Breaking News Instant updates and real-time market news.

MDR

McDermott

$1.72

0.06 (3.61%)

16:40
11/04/19
11/04
16:40
11/04/19
16:40

McDermott reports Q3 EPS ($10.37) with items, consensus (62c)

Reports Q3 revenue $2.12B, consensus $2.45B. Q3 loss includes a non-cash accounting charges of $1.5B related to impairments of goodwill and intangible assets and $256M of changes in project gross profit on specified projects identified in a covenant of our new Superpriority Credit Agreement. The company said, "We experienced continued strong backlog, with several significant customer project awards, including the Ichthys Phase 2a Gas Field Development Project in Australia, which we developed in conjunction with our integrated subsea-solutions partner, Baker Hughes, as well as a large LNG tank project on the U.S. Gulf Coast. We also achieved solid operating results in our MENA, Asia Pacific, Europe, Africa, Russia and Caspian (EARC) and Technology segments. At the same time, our capital structure continues to be pressured by certain legacy CB&I projects. Our recently announced $1.7B financing agreement with our lenders signals their confidence in our underlying business. We continue working with them to achieve a long-term balance sheet solution as we remain focused on delivering value for our customers, employees, subcontractors, and suppliers."

MDR McDermott
$1.72

0.06 (3.61%)

09/11/19
SBSH
09/11/19
NO CHANGE
Target $7
SBSH
Neutral
McDermott price target lowered to $7 from $11 at Citi
Citi analyst Andrew Kaplowitz lowered his price target for McDermott to $7 from $11 while keeping a Neutral rating on the shares. While the analyst sees "some light at the end of the tunnel" for the company on its two "troublesome" liquefied natural gas projects and believes the negative estimate revisions for CBI Legacy work may be behind the company, he says he can't rule out "further project-related noise." Further, McDermott's balance sheet is still relatively levered and some uncertainty regarding the timing of asset sales remains, Kaplowitz tells investors in a research note.
09/19/19
SBSH
09/19/19
NO CHANGE
Target $7
SBSH
Neutral
Citi sees working capital unwind as 'legitimate risk' for McDermott
Shares of McDermott dropped 63% yesterday following news that the company hired turnaround firm AlixPartners for "strategic and operational advice." Low liquidity, high leverage, and lingering headwinds associated with legacy CB&I-related projects pose elevated risk for the company, Citi analyst Andrew Kaplowitz tells investors in a research note. The analyst admits that he does not know what's causing McDermott to turn to AlixPartners. He sees a "wide range of possibilities with little visibility to near-term outcomes," which leads to his continued Neutral rating on the shares. McDermott has a "considerable amount of good assets" that are saleable and customers have an incentive to see the company succeed, says Kaplowitz. However, a working capital unwind is now a "legitimate risk" and it may be harder for McDermott to win work at this point, adds the analyst.
09/20/19
FBCO
09/20/19
NO CHANGE
Target $7
FBCO
Neutral
McDermott's plans to sell Lummus 'a last resort,' says Credit Suisse
Credit Suisse analyst Jamie Cook says McDermott's announcement that it will explore selling its Lummus technology business was considered "a last resort," but was "unfortunately needed" to improve the balance sheet. Cook, who maintains a Neutral rating and $7.00 price target, says she believes McDermott would prefer to retain some ownership in order to retain rights to be the first bidder on the EPC business if possible. She feels a transaction could occur "quickly," given the asset was already on the market recently and says she believes the stock should rally on this news given the dramatic sell off this week and that management is not considering chapter 11.

TODAY'S FREE FLY STORIES

BHVN

Biohaven Pharmaceutical

$53.79

-0.235 (-0.44%)

07:32
12/06/19
12/06
07:32
12/06/19
07:32
Hot Stocks
Biohaven's troriluzole successfully advances past interim futility analysis »

Biohaven announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$60.11

-89.11 (-59.72%)

07:30
12/06/19
12/06
07:30
12/06/19
07:30
Recommendations
Sage Therapeutics analyst commentary  »

Sage Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRIS

Curis

$1.86

0.045 (2.48%)

07:29
12/06/19
12/06
07:29
12/06/19
07:29
Hot Stocks
Curis provides updated results from Phase 1 dose escalation study of CA-4948 »

Curis announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

XNCR

Xencor

$40.63

0.05 (0.12%)

07:29
12/06/19
12/06
07:29
12/06/19
07:29
Conference/Events
Xencor to host analyst & investor meeting »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

MRVL

Marvell

$23.44

-0.48 (-2.01%)

07:27
12/06/19
12/06
07:27
12/06/19
07:27
Recommendations
Marvell analyst commentary  »

Marvell price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 06

    Jan

SON

Sonoco

$59.91

-0.04 (-0.07%)

07:25
12/06/19
12/06
07:25
12/06/19
07:25
Conference/Events
Sonoco to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 09

    Dec

  • 13

    Dec

RRC

Range Resources

$3.59

0.01 (0.28%)

07:23
12/06/19
12/06
07:23
12/06/19
07:23
Downgrade
Range Resources rating change  »

Range Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MR

Montage Resources

$5.30

0.09 (1.73%)

07:22
12/06/19
12/06
07:22
12/06/19
07:22
Upgrade
Montage Resources rating change  »

Montage Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

TGTX

TG Therapeutics

$7.68

-0.51 (-6.23%)

07:19
12/06/19
12/06
07:19
12/06/19
07:19
Conference/Events
TG Therapeutics to host investor & analyst meeting »

Investor & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

SAGE

Sage Therapeutics

$60.11

-89.11 (-59.72%)

07:15
12/06/19
12/06
07:15
12/06/19
07:15
Downgrade
Sage Therapeutics rating change  »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$8.36

-0.42 (-4.78%)

07:15
12/06/19
12/06
07:15
12/06/19
07:15
Conference/Events
Aquestive Therapeutics to host investor & analyst meeting »

Investor & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

PHG

Philips

07:13
12/06/19
12/06
07:13
12/06/19
07:13
Upgrade
Philips rating change  »

Morgan Stanley upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OKTA

Okta

$119.18

-2.64 (-2.17%)

07:13
12/06/19
12/06
07:13
12/06/19
07:13
Recommendations
Okta analyst commentary  »

Okta price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

SAGE

Sage Therapeutics

$60.11

-89.11 (-59.72%)

07:10
12/06/19
12/06
07:10
12/06/19
07:10
Recommendations
Sage Therapeutics analyst commentary  »

Sage Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNST

Constellation Pharmaceuticals

$42.66

-3.34 (-7.26%)

07:08
12/06/19
12/06
07:08
12/06/19
07:08
Conference/Events
Constellation Pharmaceuticals to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

PBYI

Puma Biotechnology

$7.43

-1.52 (-16.98%)

07:07
12/06/19
12/06
07:07
12/06/19
07:07
Initiation
Puma Biotechnology initiated  »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$31.94

0.17 (0.54%)

07:06
12/06/19
12/06
07:06
12/06/19
07:06
Initiation
MGM Resorts initiated  »

MGM Resorts initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OKTA

Okta

$119.18

-2.64 (-2.17%)

07:05
12/06/19
12/06
07:05
12/06/19
07:05
Recommendations
Okta analyst commentary  »

Okta traction in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

RCKT

Rocket Pharmaceuticals

$19.76

0.54 (2.81%)

07:05
12/06/19
12/06
07:05
12/06/19
07:05
Hot Stocks
Rocket Pharmaceuticals announces first patient treated in Phase 2 RP-L102 study »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

UCBJY

UCB

$0.00

(0.00%)

07:05
12/06/19
12/06
07:05
12/06/19
07:05
Hot Stocks
UCB: Phase 3 BE SURE results met co-primary, ranked secondary endpoints »

UCB announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLG

SL Green Realty

$85.75

-0.08 (-0.09%)

07:05
12/06/19
12/06
07:05
12/06/19
07:05
Conference/Events
SL Green Realty to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

TELA

Tela Bio

$12.11

-1.09 (-8.26%)

07:04
12/06/19
12/06
07:04
12/06/19
07:04
Hot Stocks
Tela Bio awarded contract with HealthTrust Purchasing Group »

TELA Bio announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ULTA

Ulta Beauty

$236.09

-3.27 (-1.37%)

07:03
12/06/19
12/06
07:03
12/06/19
07:03
Recommendations
Ulta Beauty analyst commentary  »

Ulta Beauty results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Mar

APLT

Applied Therapeutics

$21.78

-2.56 (-10.52%)

07:02
12/06/19
12/06
07:02
12/06/19
07:02
Hot Stocks
Applied Therapeutics to present pre-clinical data highlighting AT-001 »

Applied Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$0.81

-0.0175 (-2.10%)

07:02
12/06/19
12/06
07:02
12/06/19
07:02
Hot Stocks
McDermott, Chiyoda, Zachry Group announce first liquid from Freeport LNG Train 2 »

McDermott with its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.